Vjhemonc Podcast

Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for... The post The Lymphoma Sessions: highlights from ASH 2020 appeared first on VJHemOnc.

The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the... The post The MDS Sessions: Giants in MDS appeared first on VJHemOnc.

The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as... The post Latest therapies in AML: IMGN632, magrolimab & gilteritinib appeared first on VJHemOnc.

The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European... The post VJSession: EBMT/EHA CAR-T Nursing Session appeared first on VJHemOnc.

Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,... The post The Myeloma Sessions: key updates from ASH 2020 appeared first on VJHemOnc.

Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many... The post The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs appeared first on VJHemOnc.

During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the... The post Updates for the management of MDS from ASH 2020 appeared first on VJHemOnc.

Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm... The post The AML Sessions: highlights from ASH 2020 appeared first on VJHemOnc.

The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS... The post The MDS Sessions: treating MDS around the world appeared first on VJHemOnc.

Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble... The post Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data appeared first on VJHemOnc.

Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically... The post Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020 appeared first on VJHemOnc.

The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of... The post Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights appeared first on VJHemOnc.

Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into... The post Advances in CAR T-cell therapies for lymphoma from ASH 2020 appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells... The post Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020 appeared first on VJHemOnc.

Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute... The post The MDS sessions: lower-risk disease appeared first on VJHemOnc.

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are seen in 30% of all acute myeloid leukemia (AML) cases,... The post The AML Sessions: FLT3-mutated disease appeared first on VJHemOnc.

This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL)... The post The Lymphoma Sessions: highlights from iwNHL 2020 appeared first on VJHemOnc.

Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute... The post The MDS sessions: clinical trial participation, endpoints & approvals appeared first on VJHemOnc.

The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms... The post The AML Sessions: Venetoclax-based regimens appeared first on VJHemOnc.

IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown... The post The AML Sessions: IDH inhibitors appeared first on VJHemOnc.